For COVID-19 vaccine updates, please review our information guide and sign up for Connect. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Warning message

The subscription service is currently unavailable. Please try again later.

News

Promising results for Lenalidomide-Rituximab treatment in mantle cell lymphoma

Monday, December 8, 2014

Jia Ruan, M.D., Ph.D., an associate professor at Weill Cornell Medical College, reported at the recent ASH conference about sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL).

This is the first phase II study to explore the combination of rituximab and lenalidomide, Ruan notes. The study enrolled 38 patients with MCL, of which 84.2 percent responded to therapy. The complete remission rate with the combination was 52.6 percent. The median progression-free survival was not reached after an average of two years on therapy. These findings are remarkable, Ruan states, and demonstrated a meaningful response rate and duration.

Video originally appeared on the OncLive site.